Latest news with #COBENFY
Yahoo
21-07-2025
- Business
- Yahoo
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer
We recently published . Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently discussed. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies. It has long been one of Cramer's favorite stocks as the CNBC TV host has been nothing but full of optimism about its COBENFY schizophrenia drug. However, during this show, he changed his tone and pinned all hopes on COBENFY's success: '[Report about the two selling Eliquis at a discount] Yeah, I mean, mistakes I've made a few but, today I'm looking at Bristol, Bristol better come through with this. With this mental health, with this mental health drug that they bought, the schizophrenic drug. . . .I mean Bristol is uh, Bristol's bad. And I own it. I own it because of this schizophrenia drug. And I said yesterday to the club, they get this schizophrenia drug, I'm going with it. They don't get this schizophrenia drug, I've never heard of it. That's where I am. Never heard of Bristol-Myers.' A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Previously, Cramer discussed Bristol-Myers Squibb Company (NYSE:BMY)'s 'faint pulse': 'Of course, some of the rally's nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in the sun. I wish I had something good to say about them. Maybe it's enough to say that Bristol Myers has a faint pulse, one that lasted until the end of the session.' While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
06-06-2025
- Business
- Yahoo
Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?
We recently published a list of In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against other stocks that Jim Cramer discusses. In an older segment, a long-time listener asked about Bristol-Myers Squibb Co. (NYSE:BMY) given its dividend and drug pipeline. Cramer wasn't optimistic and said he'd prefer Pfizer for yield-focused investors. He stated: 'I think that you're going to be paid to wait for things… but it's going to be a long wait. If I want to be paid to wait, I'd rather be in Pfizer than I would be in Bristol-Myers.' Cramer picked the wrong name, as BMY rose +15.13% while Pfizer lagged. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company focused on developing drugs for cancer, cardiovascular disease, and immunological disorders. Although Cramer holds the stock in his charitable trust, he's still waiting for it to bottom before buying back into it. Here are his comments from May 14: 'Let's get started with the stocks that sold off hard today, because I think it's really important, because you know most, if not all, of these companies. Why don't we start with Bristol Myers, which we own for the Charitable Trust? Now here's a drug company with a decent oncology franchise that happens to be facing what's known as a huge patent cliff, alright… meaning it's about to have some highly lucrative drugs lose their patent protection, therefore not make them much money at all. We own it in part because of the yield. They're paying you to wait for new drugs that turn things around. The chief one is COBENFY. It's a potentially revolutionary drug that treats some tough neurological problems, including schizophrenia. Now we sold some of this stock when it had this ridiculous spike right here… some bizarre rotation into safety, but now Bristol's in the mid-40s. Now, we haven't bought back all of the stock that we sold. We're waiting for it to bottom because its most recent studies using COBENFY, it's one study, it came up snake eyes. Management has said over and over again that it can pay the dividend, which gives you a 5.6% yield. Why not buy more? Honestly, because I think it can go lower still without evidence that COBENFY is doing better.' A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Overall, BMY ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?
We recently published a list of In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands against other stocks that Jim Cramer discusses. In an older segment, a long-time listener asked about Bristol-Myers Squibb Co. (NYSE:BMY) given its dividend and drug pipeline. Cramer wasn't optimistic and said he'd prefer Pfizer for yield-focused investors. He stated: 'I think that you're going to be paid to wait for things… but it's going to be a long wait. If I want to be paid to wait, I'd rather be in Pfizer than I would be in Bristol-Myers.' Cramer picked the wrong name, as BMY rose +15.13% while Pfizer lagged. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company focused on developing drugs for cancer, cardiovascular disease, and immunological disorders. Although Cramer holds the stock in his charitable trust, he's still waiting for it to bottom before buying back into it. Here are his comments from May 14: 'Let's get started with the stocks that sold off hard today, because I think it's really important, because you know most, if not all, of these companies. Why don't we start with Bristol Myers, which we own for the Charitable Trust? Now here's a drug company with a decent oncology franchise that happens to be facing what's known as a huge patent cliff, alright… meaning it's about to have some highly lucrative drugs lose their patent protection, therefore not make them much money at all. We own it in part because of the yield. They're paying you to wait for new drugs that turn things around. The chief one is COBENFY. It's a potentially revolutionary drug that treats some tough neurological problems, including schizophrenia. Now we sold some of this stock when it had this ridiculous spike right here… some bizarre rotation into safety, but now Bristol's in the mid-40s. Now, we haven't bought back all of the stock that we sold. We're waiting for it to bottom because its most recent studies using COBENFY, it's one study, it came up snake eyes. Management has said over and over again that it can pay the dividend, which gives you a 5.6% yield. Why not buy more? Honestly, because I think it can go lower still without evidence that COBENFY is doing better.' A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Overall, BMY ranks 7th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at .
Yahoo
16-05-2025
- Business
- Yahoo
Jim Cramer On Bristol-Myers Squibb: 'Waiting For It To Bottom'
Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first on his list as he said: 'Let's get started with the stocks that sold off hard today, because I think it's really important, because you know most, if not all, of these companies. Why don't we start with Bristol Myers, which we own for the Charitable Trust? Now here's a drug company with a decent oncology franchise that happens to be facing what's known as a huge patent cliff, alright… meaning it's about to have some highly lucrative drugs lose their patent protection, therefore not make them much money at all. We own it in part because of the yield. They're paying you to wait for new drugs that turn things around. The chief one is COBENFY. It's a potentially revolutionary drug that treats some tough neurological problems, including schizophrenia. Now we sold some of this stock when it had this ridiculous spike right here… some bizarre rotation into safety, but now Bristol's in the mid-40s. Now, we haven't bought back all of the stock that we sold. We're waiting for it to bottom because its most recent studies using COBENFY, it's one study, it came up snake eyes. Management has said over and over again that it can pay the dividend, which gives you a 5.6% yield. Why not buy more? Honestly, because I think it can go lower still without evidence that COBENFY is doing better.' A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Bristol-Myers Squibb Company (NYSE:BMY) develops treatments for different diseases across several medical fields. While we acknowledge the potential of BMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: Jim Cramer Put These 8 Stocks Under a Microscope Recently and Jim Cramer Commented on These 6 Natural Gas Players Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Jim Cramer On Bristol-Myers Squibb: 'Waiting For It To Bottom'
Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first on his list as he said: 'Let's get started with the stocks that sold off hard today, because I think it's really important, because you know most, if not all, of these companies. Why don't we start with Bristol Myers, which we own for the Charitable Trust? Now here's a drug company with a decent oncology franchise that happens to be facing what's known as a huge patent cliff, alright… meaning it's about to have some highly lucrative drugs lose their patent protection, therefore not make them much money at all. We own it in part because of the yield. They're paying you to wait for new drugs that turn things around. The chief one is COBENFY. It's a potentially revolutionary drug that treats some tough neurological problems, including schizophrenia. Now we sold some of this stock when it had this ridiculous spike right here… some bizarre rotation into safety, but now Bristol's in the mid-40s. Now, we haven't bought back all of the stock that we sold. We're waiting for it to bottom because its most recent studies using COBENFY, it's one study, it came up snake eyes. Management has said over and over again that it can pay the dividend, which gives you a 5.6% yield. Why not buy more? Honestly, because I think it can go lower still without evidence that COBENFY is doing better.' A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. Bristol-Myers Squibb Company (NYSE:BMY) develops treatments for different diseases across several medical fields. While we acknowledge the potential of BMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: Jim Cramer Put These 8 Stocks Under a Microscope Recently and Jim Cramer Commented on These 6 Natural Gas Players Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
